Join us for the 2019 Healthcare Entrepreneurship & Innovation Exchange hosted by the UNC Kenan-Flagler Business School Healthcare Club and the Center for the Business of Health.
Please join Center for the Business of Health alumni board members and Markus Saba, Executive Director for the UNC Center for the Business of Health, to discuss the current state of Healthcare in the United States.
Access challenges associated with high-cost pharmaceuticals have jump started discussion of solutions ranging from state-based boards reviewing drug price increases to harnessing Medicare’s purchasing power for “price negotiation” to old-fashioned price-setting.
This conference brings together students, executives from the private sector, academic researchers and public policy leaders to discuss the most pressing problems in healthcare today.
 

Related Publications

New Drugs, New Ideas: Payment Policy Innovations for High-Cost Pharmaceuticals

October 01, 2019

Access challenges associated with high-cost pharmaceuticals have jump started discussion of solutions ranging from state-based boards reviewing drug price increases to harnessing Medicare’s purchasing power for “price negotiation” to old-fashioned price-setting. More

How FDA Can Act On E-Cigarettes And Protect The Public Health

September 19, 2019

After years of decline, increases in American youth tobacco usage have pushed the tobacco control debate back into the forefront of the public health conversation. Youth tobacco use increased from 2011 to 2018, largely driven by e-cigarette usage, which grew from 1.5% to 20.8% of American high school students, representing an increase of 2.83 million adolescents. Despite extensive evidence that e-cigarette chemicals cause morbidity including immediate, harmful changes in endothelial function in healthy nonsmokers, 72% of teenage e-cigarettes users believe e-cigarettes cause some, little, or no harm. More

FTC Concerns Over Bristol-Myers Deal Raise Questions

August 05, 2019

On Jan. 3, 2019, Bristol-Myers Squibb Co. announced its proposed acquisition of Celgene Corp. for approximately $74 billion. The Federal Trade Commission issued requests for additional information and documentary materials to the companies on March 25, 2019, that were “focused on marketed and pipeline products for the treatment of psoriasis.” In order to address the FTC’s concerns, BMS plans to divest Celgene’s Otezla (apremilast) drug, which is a phosphodiesterase-4 inhibitor indicated for the treatment of moderate to severe psoriasis and psoriatic arthritis. Psoriasis is an autoimmune disease with multiple subtypes, with large skin plaques being the most common manifestation.   More

Pricing Power And New Prescription Drugs

August 01, 2019

The pricing of prescription drugs comes under persistent public scrutiny, yet limited empirical evidence details the determinants of these price levels. This study provides a price function specification for newly launched drugs, with marginal cost and pricing power components.

More